Fr. 169.00

Green Chemistry in the Pharmaceutical Industry

English · Hardback

Shipping usually within 1 to 3 weeks (not available at short notice)

Description

Read more

Edited by three of the world s leading pharmaceutical scientists, this is the first book on this important and hot topic, containing much previously unpublished information. As such, it covers all aspects of green chemistry in the pharmaceutical industry, from simple molecules to complex proteins, and from drug discovery to the fate of pharmaceuticals in the environment. Furthermore, this ready reference contains several convincing case studies from industry, such as Taxol, Pregabalin and Crestor, illustrating how this multidisciplinary approach has yielded efficient and environmentally-friendly processes. Finally, a section on technology and tools highlights the advantages of green chemistry.

List of contents

INTRODUCTION TO GREEN CHEMISTRY, ORGANIC SYNTHESIS AND PHARMACEUTICALSThe Development of Organic SynthesisThe Environmental FactorThe Role of CatalysisGreen Chemistry: Benign by DesignIbuprofen ManufactureThe Question of Solvents: Alternative Reaction MediaBiocatalysis: Green Chemistry Meets White BiotechnologyConclusions and ProspectsGREEN CHEMISTRY METRICSIntroductionMeasuring Resource UsageLife Cycle Assessment (LCA)Measuring Chemistry and Process EfficiencyMeasuring Process Parameters and EmissionsReal Time AnalysisOperational EfficiencyMeasuring EnergyMeasuring the Toxicity of All the SubstratesMeasuring Degradation PotentialMeasuring the Inherent Safety of Lack of Inherent SafetyConclusionsSOLVENT USE AND WASTE ISSUESIntroduction to Solvent Use and Waste IssuesSolvent and Process Greenness Scoring and Selection ToolsWaste Minimization and Solvent RecoveryENVIRONMENTAL AND REGULATORY ASPECTSHistorical PerspectivePharmaceuticals in the EnvironmentEnvironmental RegulationsA Look to the FutureSYNTHESIS OF SITAGLIPTIN, THE ACTIVE INGREDIENT IN JANUVIA AND JANUMETIntroductionFirst-Generation RouteSitagliptin through Diastereoselective Hydrogenation of an Enamine. The PGA Enamine-Ester RouteThe Triazole FragmentDirect Preparation of Beta-Keto AmidesSecond-Generation Chiral Auxiliary Route. The PGA Enamine-Amide RoutePrufication and Isolation of Sitagliptin (Pharmaceutical Form)The Final Manufacturing RouteTHE DEVELOPMENT OF SHORT, EFFICIENT, ECONOMIC, AND SUSTAINABLE CHEMOENZYMATIC PROCESSES FOR STATIN SIDE CHAINSIntroduction: BiocatalysisThe Relevance of StatinsBiocatalytic Routes to Statin Side Chains2-Deoxy-D-Ribose 5-Phosphate Aldolase (DERA)-Based Routes to Statin IntermediatesConclusionsTHE TAXOL STORY-DEVELOPMENT OF A GREEN SYNTHESIS VIA PLANT CELL FERMENTATIONIntroductionDiscovery and Early DevelopmentFrom Extraction of Taxol from Pacific Yew Tree Bark to Semi-Synthetic TaxolTaxol from Plant Cell FermentationComparison of Semi-Synthetic versus PCF Taxol Processes: The Environmental ImpactComparison of Semi-Synthetic versus PCF Taxol: Green Chemistry PrinciplesFinal WordsTHE DEVELOPMENT OF A GREEN, ENERGY EFFICIENT, CHEMOENZYMATIC MANUFACTURING PROCESS OF PREGABALINIntroductionProcess Routes to PregabalinBiocatalytic Route to PregabalinGreen Chemistry ConsiderationsConclusionsGREEN PROCESSES FOR PEPTIDE MIMETIC DIABETIC DRUGSIntroductionGreen Chemistry Considerations in Peptide-like API manufacturePurification Process to Manufacture Amorphous APIPreparation of Unnatural Amino AcidsSummaryTHE DEVELOPMENT OF AN ENVIRONMENTALLY SUSTAINABLE PROCESS FOR RADAFAXINEIntroductionChemistry Process and the Dynamic Kinetic Resolution (DKR)Multicolumn Chromatography - Development of Route 4Environmental AssessmentSummaryCONTINUOUS PROCESSING IN THE PHARMACEUTICAL INDUSTRYIntroductionContinuous Production of a Key Intermediate for AtorvastatinContinuous Process to Prepare CelecoxibContinuous Oxidation of Alcohols to AldehydesContinuous Production of BromonitromethaneContinuous Production and Use of DiazomehtaneA Snapshot of Some Further Continuous Processes Used in the Preparation of Pharmaceutical AgentsConclusionsPREPARATIVE AND INDUSTRIAL SCALE CHROMATOGRAPHY: GREEN AND INTEGRATED PROCESSESIntroductionBasic Principles of ChromatographyProcess Optimization to Reduce Eluent ConsumptionUse of a Green Solvent: Supercritical Carbon DioxideSolvent Recycling TechnologiesApplication ExamplesConclusion: An Environmentally Friendly Solution for Each SeparationDYNAMIC RESOLUTION OF CHIRAL AMINE PHARMACEUTICALS: TURNING WASTE ISOMERS INTO USEFUL PRODUCTBackgroundIntegration of Chiral Amine Resolution and RacemizationCase StudiesConclusionsGREEN TECHNOLOGIES IN THE GENERIC PHARMACEUTICAL INDUSTRYIntroduction'Waste': Definition and RemedyAmidationSynthesis of GalanthamineSynthesis of SolefinacinSynthesis of LevetiracetamSynthesis of a Finasteride IntermediateBrominationSulfoxidation in the Synthesis of RabeprazoleConclusionsENVIRONMENTAL CONSIDERATIONS IN BIOLOGICS MANUFACTUREIntroductionTherapeutic BiologicsEnvironmental Impact ConsiderationsOverall ComparisonEnvironmental Indices for Therapeutic Protein ManufactureTechnologies with Potential Environmental ImpactSingle-Use Biologics ManufactureSummaryFUTURE TRENDS FOR GREEN CHEMISTRY IN THE PHARMACEUTICAL INDUSTRYIntroductionWaste Minimization in Drug DiscoveryGreener Synthetic Methods in Primary ManufacturingAlternative Solvents in the Pharmaceutical IndustryGreen Chemistry in Secondary Pharmaceutical OperationsGlobal Cooperation in Green ChemistryConclusions

About the author

Andy Wells is a Principal Scientist in the AstraZeneca Global Process R&D Group. Following a BSc and PhD at Essex University he joined Chemical Development at SmithKline & French in 1986, (SmithKline Beecham in 1989). Experienced in all aspects of organic synthesis and scale-up, he has special interests in chemo-catalysis, biocatalysis and green chemistry. Whilst at SmithKline Beecham he won a corporate Green Chemistry/Technology award in 1999. He currently leads the AstraZeneca Green Chemistry group and is co-chair of American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable. He is also on the international advisory board of the journal, ChemSusChem.

Michael Williams joined Pfizer in 1972 following his PhD with Professor Charles Rees (University of Liverpool), and rose to become Executive Director and Departmental Head of UK Chemical R&D in 2003. His mid-career responsibilities included the Medicinal Chemistry interface, outsourcing initiatives and technology adoption. In addition to his experience with about 50 early drug candidates, he played a significant role in the late development, filing and commercialization of many agents including ZoloftTM, ViagraTM and RelpaxTM. Since retiring from Pfizer in late 2007, he has become an independent CMC consultant.

Summary

Von drei weltbekannten Pharmazeuten herausgegeben, widmet sich dieser Band erstmals der "grünen" Chemie im Umfeld der pharmazeutischen Industrie. Dabei geht es um einfache kleine Moleküle genauso wie um komplexe Proteine, um pharmazeutische Grundlagenforschung und um das Schicksal von Wirkstoffen in der Umwelt. Die handliche Monographie enthält zahlreiche bisher nicht publizierte Informationen, dazu überzeugende Fallstudien aus der Industrie (Taxol, Pregabalin, Crestor etc.), die zeigen, inwieweit ein multidisziplinärer Ansatz Effizienz und Umweltfreundlichkeit der Prozesse befördern kann. Ein abschließendes Kapitel befasst sich mit eindrucksvollen Technologien und technischen Hilfsmitteln.

Report

"At last! A book which looks at Green Chemistry from an industrial viewpoint! This is the best book I have read on Green Chemistry and should be on the bookshelf of every process chemist and engineer. Outstanding!" ( Organic Process Research & Development , March 2010)

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.